RxDoctor Payments DataLook up a doctor →

Ashley Beikmann, APRN

Family · Lawrenceville, GANPI 1013426675

Payments from drug & device makers

$16,066in general payments, 2019–2025

Across 917 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • Paratek Pharmaceuticals, Inc.$1K
  • Amgen$906
  • Lilly USA, LLC$763
  • plus $8K from 44 others

What the payments were for

  • Food & beverage$15,94699%
  • Education$1201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,066 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$30,915
Medicare patients
172
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$43,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$31,646
ProliaDenosumab18$30,855
JardianceEmpagliflozin28$27,138
MounjaroTirzepatide22$22,959
FarxigaDapagliflozin Propanediol21$17,369
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$16,128
Repatha SureclickEvolocumab17$15,708
XareltoRivaroxaban21$15,406
MyrbetriqMirabegron22$14,481
Rosuvastatin Calcium155$2,231
Ezetimibe37$2,153
Fenofibrate42$1,346
SynthroidLevothyroxine Sodium23$1,271
Losartan Potassium129$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,848$43,76338 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,521$33,49733 claims
GSKTrelegy Ellipta$525$31,64626 claims
AmgenProlia$906$30,85518 claims
Boehringer IngelheimJardiance$109$27,13828 claims
Lilly USA, LLCMounjaro$763$22,95922 claims
Johnson & JohnsonXarelto$22$15,40621 claims
Astellas Pharma US IncMyrbetriq$260$14,48122 claims
AbbVieSynthroid$1,693$1,27123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →